LENZ logo

LENZ THERAPEUTICS INC

LENZNASDAQ
🏆 #3993 by market capUS Equity
$678.47▼ $47.90 (−7.06%)
Simulated price
🔔
Track LENZ
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 7.1%
7d▲ 16367.7%
14d▲ 15958.5%
30d▲ 13164.3%
ytd▲ 4145.7%
1y▲ 1412.9%
🏦Market Cap
$124M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
5.8x
Fair
Otter Score
60
Fair

Trading Snapshot

Day Range
$673.57 – $691.52
52-Week Range
$3.60 – $50.40
Volume
$2.95B
Avg Volume
$3.35B
Shares Outstanding
31.4M
Next Earnings
Nov 29, 2026

Fundamentals Snapshot

Annual Revenue
$19M
Last Q Revenue
$5M
P/E Ratio
—
P/S Ratio
5.8x
EPS (TTM)
$-4.08
Dividend Yield
—
Dilution (1yr)
+13.0%

Why Investors Own LENZ

  • ✓High-growth profile — revenue up +22.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 41% gross margin and 12% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

LENZ logo

LENZ THERAPEUTICS INC

LENZ
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$19M▲ +0.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
96.3%▼ −3.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$91M▲ +55.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$70M▲ +16.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
31.1M▲ +13.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$24M▲ +$6M YoY
StockOtter · stockotter.space

About LENZ THERAPEUTICS INC

LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$893.59
▲ +31.7% Upside
High Target$1,119.63
Low Target$728.63
Based on 34 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

LENZ THERAPEUTICS INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift LENZ price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

LENZ THERAPEUTICS INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.